About AbSci
AbSci is a publicly listed company based in Vancouver (United States) founded in 2011. AI-based technology is used for recombinant protein production in therapeutics. It operates in the Healthcare and Technology sectors. AbSci has raised $227.56 million across 7 funding rounds from investors including Fidelity Investments, AGC and KBI Biopharma. The company has 157 employees. AbSci has completed 2 acquisitions, including Denovium and Totient. Its website absci.com draws about 21 thousand monthly visits. AbSci offers products and services including Drug Creation Platform and AI Target Discovery. Its focus areas include High Tech, Generative AI, Industry Specific Applications and Drug Discovery. Its legal entity is Absci Corp.
Company details
AbSci was founded in 2011 and is based in Vancouver, United States. An integrated platform is offered in the biotechnology sector, where biologic drug discovery and cell line development are combined into one process. Recombinant proteins for therapeutic uses are produced through AI-driven methods. This approach supports the generation of novel biologics, with operations centered on advancing protein engineering for medical applications.
- Annual Revenue$2.8 M (USD)-38.24as on Dec 31, 2025
- Net Profit-$115.18 M (USD)-11.71as on Dec 31, 2025
- EBITDA-$112.98 M (USD)-18.3as on Dec 31, 2025
- Total Equity Funding$227.56M (USD)
in 7 rounds
- Latest Funding Round$125M (USD), Series E
Mar 2021
- InvestorsFidelity Investments
& 15 more
- Employee Count157
- Investments & AcquisitionsDenovium
& 1 more
Products & Services of AbSci
AbSci offers a comprehensive portfolio of products and services, including Drug Creation Platform and AI Target Discovery.
Integrates AI for biologics design and optimization in drug development.
Uses reverse immunology to find novel targets for antibody optimization.
Apps and channels of AbSci
its YouTube channel Absci has 565 subscribers and 15 videos.
Videos from AbSci
The most watched videos on AbSci's YouTube channel, Absci (565 subscribers). Click a video to play it here.
More on Absci.
Funding Insights of AbSci
AbSci has successfully raised a total of $227.56M across 7 strategic funding rounds. The most recent funding activity was a Series E round of $125 million completed in March 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $227.56M
- Total Rounds 7
- Last Round Series E — $125M
- First Round $5.1M
(Apr 2016)
- Investors Count 16
All 7 funding rounds of AbSci with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2021 | $125M | Series E | – | Casdin Capital, Redmile Group | |
| Oct 2020 | $70M | Series E | – | Casdin Capital | |
| Jan 2020 | $5M | Debt – Conventional | – | – | – |
| Dec 2019 | $10.36M | Series D | – | KBI Biopharma, JSR Life Sciences | |
| May 2018 | $12M | Series C | – | AGC | |
| Apr 2016 | $5.1M | Series A | – | Phoenix Venture Partners | – |
| Apr 2016 | $5.1M | Series A | – | – |
16 investors in total: 16 institutional.
Investors in AbSci
AbSci has secured backing from 16 investors, including venture fund and institutional investors. Prominent investors backing the company include Fidelity Investments, AGC and KBI Biopharma.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investing in Life Sciences sectors like Healthcare and Biotechnology. | casdincapital.com | |||
Early-stage startups are invested in by sector-agnostic VC fund. | irvinginvestors.com | New York, United States | ||
Venture capital investments in healthcare are focused on by aMoon. | amoon.fund | |||
Health-tech companies are targeted for venture capital investments. | 1999 | perceptivelife.com | New York, United States | |
Venture capital firm funding transformative technologies | phoenix-vp.com | San Mateo, United States | ||
Corporate-backed venture capital is focused on the life science sector. | merckghifund.com | Kenilworth, United States | ||
Funding is provided to innovative startups in Oregon. | oregonventurefund.com | United States | ||
Columbia Ventures Corporation is engaged in private equity investments. | 1988 | colventures.com | Vancouver, United States | |
Early-stage investments are made in Washington-based startups by WRF Capital. | wrfcapital.com | Seattle, United States | ||
Operates as an employee-owned hedge fund focused on long/short equity strategies. | 2007 | redmilegroup.com | San Francisco, United States |
Investor details for AbSci
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of AbSci
28 people are tracked at AbSci (14 in leadership, 5 in board & advisors, 9 in team); the tracked headcount is 157.
| Name | Role | Group |
|---|---|---|
Sean McClain | Leadership | |
Karin Wierinck | Chief People Officer | Leadership |
Andreas Busch | Chief Innovation Officer | Leadership |
Nikhil Goel | Chief Strategy Officer | Leadership |
Jared Sharp | Associate Director | Leadership |
Michael Mangone | Vice President Of Business Development | Leadership |
Beverly Crider | Director, Alliance Management | Leadership |
Yukte Sharma- Dayal | Sr. Executive Assitant To CEO And CFO | Leadership |
Mario Sanches | Director Of Business Development | Leadership |
Wen Sha | Vp, Chief Of Staff | Leadership |
Chris Ulm | VP, Business Development & Alliance Management | Leadership |
Ben Golomb | Associate Director, Alliance Management & Growth Strategy | Leadership |
Tom Cordaro | Vice President Of Business Development | Leadership |
Chad Taylor | Head Of IT | Leadership |
Zachariah Jonasson | Chairman | Board & advisors |
V. Bryan Lawlis | Director | Board & advisors |
Gustavo Mahler | Director | Board & advisors |
Andy Pihl | Director | Board & advisors |
Dan Gold | Director | Board & advisors |
Christine Lemke | SVP, Portfolio & Growth Strategy | Team |
8 more people are available in the full profile.
Complete people profiles for AbSci
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of AbSci
AbSci is a publicly listed company on the NASDAQ with ticker symbol ABSI in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date22 Jul 2021
- Listed onNASDAQ: ABSI
- Listed entityAbsci Corporation
- Exchange sectorHealth technology
- ISINUS00091E1091
- Share price$9.10 (-5.89% on the day) · 2026-10-13
- Market capitalisation$1.56B
- EPS (diluted, trailing year)$-0.80
- Volume (last session)3,047,455
Financials of AbSci
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $2.8M | -$115.2M | -$113.0M |
| 2024 | $4.5M | -$103.1M | -$95.5M |
| 2023 | $5.7M | -$110.6M | -$79.7M |
| 2022 | $5.8M | -$104.9M | -$93.7M |
| 2021 | $4.8M | -$101.0M | -$67.7M |
Detailed financial statements for AbSci
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by AbSci
AbSci has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Denovium and Totient.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Developer of a drug discovery platform for cancer and autoimmune disease by using artificial intelligence | totient.bio | Cambridge, United States | 2017 | Jun 2021 | •••• | |
AI methods and solutions are provided to the biopharma industry. | denovium.com | San Diego, United States | 2018 | Jan 2021 | •••• |
Complete acquisition details for AbSci
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of AbSci
6 dated milestones of AbSci across 10 years, from founding to its latest funding, stage changes and deals.
Web traffic of AbSci
The website of AbSci (absci.com) receives about 20.9K visits a month.
- Monthly visits20.9K
▲ 34.4% vs previous month
Top companies in Life Sciences Platforms & Tools
3 companies that operate in the same segment as AbSci (Life Sciences Platforms & Tools) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | |||
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | 1,111 | ||
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Absci
Complete news archive for AbSci
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about AbSci
AbSci was founded in 2011 and raised its 1st funding round 5 years after it was founded.
AbSci is headquartered in Vancouver, United States. It is registered at Vancouver, Washington, United States.
AbSci is a funded company, having raised a total of $227.56M across 7 funding rounds to date. The company's 1st funding round was a Series A of $5.1M, raised on Apr 2016.
AbSci has 157 employees.
Annual revenue of AbSci is $2.8M as on Dec 31, 2025.
AbSci was founded in 2011 and is based in Vancouver, United States. An integrated platform is offered in the biotechnology sector, where biologic drug discovery and cell line development are combined into one process. Recombinant proteins for therapeutic uses are produced through AI-driven methods. This approach supports the generation of novel biologics, with operations centered on advancing protein engineering for medical applications.
AbSci offers Drug Creation Platform and AI Target Discovery.
Yes, AbSci is publicly traded on NASDAQ under the ticker symbol ABSI.
AbSci has 16 investors. Key investors include Fidelity Investments, AGC, KBI Biopharma, Perceptive Advisors, and ArrowMark Partners.
AbSci operates through Absci Corp.